Preoperative Panitumumab and Radiotherapy in Rectal Cancer (PrePaRad)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00973193|
Recruitment Status : Terminated (The intermediate analyses did not allowed to continue the clinical study.)
First Posted : September 9, 2009
Last Update Posted : April 20, 2016
The purpose of this study is to investigate the activity of panitumumab in combination with standard preoperative radiotherapy in locally advanced rectal cancer, followed by complete surgery and adjuvant chemotherapy.
The main hypothesis of the study is that the association of EGFR-targeting agent and radiation therapy could be as effective or even improve the rate of pathological complete tumoral response with fewer toxicities in comparison to the standard of care using chemoradiation therapy.
|Condition or disease||Intervention/treatment||Phase|
|Rectal Cancer||Drug: panitumumab||Phase 2|
Anti-EGFR monoclonal antibodies have radiosensitizing properties. In particular, cetuximab in combination with curative-intent radiotherapy has been reported to increase median overall survival over radiation therapy alone in locally advanced head and neck carcinoma.
Similar benefit in rectal cancer is expected. However, preliminary studies revealed that the combination of chemoradiation and cetuximab did not seem to improve the pathological tumor response. However, in the past studies, the selection of patients' population was not optimal since KRAS mutational status was not considered during recruitments.
Therefore, new trials to investigate EGFR-targeting therapies in combination with radiotherapy in wild-type KRAS patients are required.
Adjuvant chemotherapy has also shown to decrease the risk of local relapse in patients who did not receive chemotherapy during radiotherapy. In our study, since there will be no chemotherapy given during the preoperative setting, the administration of adjuvant chemotherapy postoperatively is highly recommended.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Study of Preoperative Panitumumab and External Beam Radiotherapy in Patients With Locally Advanced Rectal Cancer|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||September 2011|
|Actual Study Completion Date :||December 2012|
intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
Other Name: Vectibix
- Pathological Complete Response (pCR) [ Time Frame: 11 weeks ]
- Safety, pathologic R0 resection, negative Circumferential Resection Margin, pathologic downstaging, tumor regression grade, quality of mesorectal excision, rate of sphincter-preservation, Disease-Free Survival, local control rate, translational research [ Time Frame: 24 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00973193
|Institute Jules Bordet|
|Brussels, Belgium, 1000|
|Cliniques Universitaires Saint Luc - Université Catholique de Louvain|
|Brussels, Belgium, 1200|
|Centre Hospitalier Notre Dame et Reine Fabiola|
|Charleroi, Belgium, 6000|
|Centre Hospitalier de Jolimont-Lobbes|
|La Louvière, Belgium, 7100|
|Leuven, Belgium, 3000|
|Clinique et Maternité Saint Elizabeth|
|Namur, Belgium, 5000|
|Clinique Saint Pierre|
|Ottignies, Belgium, 1340|
|Clinique Universitaire de Mont Godinne|
|Yvoir, Belgium, 5530|
|Principal Investigator:||Jean-Pascal H Machiels, MD, PhD||Cliniques universitaires Saint-Luc- Université Catholique de Louvain|